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Objectives. This study evaluated the clinical safety and long-
term results of rotational atherectomy (RA) followed by low-
pressure balloon dilatation (percutaneous transluminal coronary
angioplasty [PTCA]) for the treatment of in-stent restenosis
(ISR).
Background. In-stent restenosis is associated with a high
incidence of recurrence after interventional treatment. Because
ISR is due to neointimal hyperplasia, rotational ablation may be
a more effective treatment than PTCA.
Methods. Between November 1995 and November 1996, 100
consecutive patients with first-time ISR were treated by RA.
Quantitative coronary angiography and intravascular ultrasound
(IVUS) were used to analyze the acute procedural results. The
incidence of repeat in-stent restenosis and target vessel revascu-
larization (TVR) at follow-up was determined.
Results. Procedural success without any major in-hospital
complications was achieved in 100% of cases. Slow flow was
observed in 3% and creatine kinase-MB enzyme elevation >33
normal occurred in 2%. The mean burr-to-artery ratio was 0.68 6
0.18 and adjuvant balloon dilatation was performed at 4.2 6
2.1 atm. Minimum luminal diameter increased from 0.86 6
0.28 mm to 1.89 6 0.21 mm after RA and to 2.56 6 0.29 mm after
adjunct PTCA. Quantitative IVUS analysis showed that 77% of the
luminal gain occurred due to rotational ablation of the restenotic
tissue and only 23% occurred after adjunct balloon dilation, and
further stent expansion did not contribute to the luminal enlarge-
ment. At a mean follow-up of 13 6 5 months, repeat in-stent
restenosis occurred in 28% of patients with TVR of 26%. Univar-
iate predictors of repeat restenosis were burr-to-artery ratio <0.6,
ISR in <90 days of stenting, ostial lesion, stent for a restenotic
lesion and diffuse type ISR.
Conclusions. Rotational atherectomy is a safe and feasible
technique for treatment of ISR and is associated with a relatively
low recurrent restenosis in comparison to historical controls of
balloon angioplasty.
(J Am Coll Cardiol 1998;32:1358–65)
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In-stent restenosis (ISR) presents a novel challenge to inter-
ventional cardiologists. Although less frequent than restenosis
after balloon angioplasty (1,2), the prevalence of ISR has been
increasing along with the widespread use of stents for percu-
taneous revascularization of a wide variety of coronary lesions.
Unlike restenosis after balloon angioplasty (percutaneous
transluminal coronary angioplasty [PTCA]), which is predom-
inantly due to geometric arterial remodeling (shrinkage) up to
65% (3), ISR appears to be solely due to neointimal prolifer-
ation [intimal hyperplasia, (IH)], and intracoronary ultrasound
has shown absence of stent recoil or stent compression in this
setting (4,5). In-stent restenosis cases that are not referred for
coronary artery bypass graft surgery (CABG) have been tradi-
tionally treated by balloon angioplasty (PTCA) with recurrent
restenosis rates of up to 85%, especially after diffuse ISR
(6–9). In these cases of diffuse ISR, PTCA is limited by the
large plaque volume and leaves a relatively high residual
stenosis (20%–35%). For these reasons, pretreatment with an
atheroablative technique prior to balloon dilatation might be a
preferable treatment modality for ISR compared with PTCA
alone. Excimer laser ablation followed by adjunct balloon
dilatation recently has been reported to produce an increase in
lumen on the basis of both stent expansion and IH ablation,
and to have a trend toward a reduced target vessel revascular-
ization (TVR) rate at follow-up in comparison with PTCA
alone (10). Rotational ablation of neointimal tissue within
stents has been reported preliminarily as a feasible technique
(11,12). In this study we review our single-center results of
treatment of the first 100 consecutive ISR cases with rotational
atherectomy (RA) and adjunct balloon dilatation, including
the acute in-hospital outcome as well as recurrent ISR and
TVR rates. Intravascular ultrasound (IVUS) was performed in
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a fraction of cases to assess the mechanism of luminal enlarge-
ment in this setting.
Methods
Between November 1995 and November 1996, a total of 122
patients underwent percutaneous coronary intervention for the
treatment of a symptomatic first-time, ISR of $3.0 mm balloon
expandable stents at Mount Sinai Hospital, New York. In all
patients, initial stents were deployed using a 3.0 mm or larger
balloon inflated at high pressure (.12 atm). Of these, 16
patients were treated with PTCA and 6 with additional stent
implantation. The remaining 100 consecutive patients with 100
ISR lesions were treated with RA and comprised the study
population. In-stent restenosis was defined as .50% diameter
stenosis within or at the edges of a stented lesion that
presented at least 8 weeks after the stent deployment. All
patients were either symptomatic or ischemic by noninvasive
testing. Clinical, angiographic and procedural data were pro-
spectively recorded during hospital stay and all patients were
followed every 3 months by telephone call or physician visit.
Rotational atherectomy. Routine premedication with
325 mg of aspirin and 30 mg of oral diltiazem were used;
beta-adrenergic blocking agents were discontinued for .24 h
prior to RA in elective cases. An 8 to 10 F arterial sheath and
a temporary pacemaker via a 5 F sheath in left circumflex or
right coronary artery intervention were inserted transfemorally
in all patients. Heparin was used in repeated boluses to achieve
and maintain an activated clotting time .300 s. Abciximab
(ReoPro; Centocor, Malvern, Pennsylvania) was used at the
discretion of the interventionalist. A flushing solution contain-
ing verapamil, nitroglycerin and heparin was used routinely
during the RA. An 8 to 10 F guide catheter was selected to
accommodate the estimated final burr size. The ablation runs
were limited to 30 to 40 s at a time with slow advancement and
“pecking” motion, avoiding a .5,000 rpm drop during burring.
In the initial 40 cases, there was no set defined target burr-to-
artery ratio and it was left to the discretion of the operators. In
later cases, with experience, the target burr-to-artery ratio was
0.7. If IVUS was used prior to RA, the final burr selected had
a diameter of less than 80% of the narrowest stent diameter.
After RA, adjunct PTCA was routinely performed with a
balloon-to-artery ratio of 1:1 at an inflation pressure of
3–6 atm (required to achieve complete balloon expansion in
these ISR lesions) for 90 to 180 s. Intracoronary nitroglycerin
0.1 to 0.2 mg was administered routinely before all cineangio-
grams. Serum creatine kinase (CK)-MB enzymes were re-
corded at baseline and every 8 h for 16 to 24 h after the
procedure.
Angiographic analysis. A single operator (K.V.), using a
previously validated system of quantitative coronary angiogra-
phy on the cardiotrace analyzer (13; Cine Graphics, Grand
Prairie, TX) analyzed all cineangiograms using the contrast-
filled catheters as the calibration standard. Final results were
the average of the two orthogonal views with the least amount
of foreshortening and overlap. Reproducibility of the measure-
ments by the operator was established by random repeated
measurements. Reference vessel diameter, minimum luminal
diameter and percent diameter stenosis were measured. Le-
sion length was measured with digital calipers. Slow flow was
assessed visually and lesions were classified qualitatively ac-
cording to the American College of Cardiology/American
Heart Association (ACC/AHA) classification. Procedural suc-
cess was defined as ,30% residual diameter stenosis. Coro-
nary dissection was classified according to National Heart,
Lung and Blood Institute classification: type A–B as minor
dissection and type C–F as major dissection.
Intravascular ultrasound. To understand the mechanism
of lumen enlargement after RA, IVUS was performed in the
first 15 cases (interpretable data in 10 cases) and consecutively
in cases from 71 to 100 (interpretable data in 27 cases).
Imaging runs were done preprocedure, after RA and after
adjunct PTCA; intracoronary administration of 0.1 to 0.2 mg of
nitroglycerin preceded each imaging run. The IVUS catheter
was advanced approximately 10 mm distal to the target lesion,
and an imaging run was performed with slow manual pullback
from distal to the target lesion towards the aorto-ostial junc-
tion. Studies were recorded only during pullback onto 0.5 in,
high-resolution VHS for off-line analysis. The commercially
available Hewlett-Packard System with a 30 MHz beveled
transducer rotating at 1,800 rpm within a 3.5 F short monorail
imaging catheter was used, and was withdrawn manually with
fluoroscopic guidance to obtain the image sequence. All data
were analyzed by the same investigator (S.D.), who performed
quantitative measurements (cross-sectional area [CSA]) in the
lesion at each imaging run (14,15). Stent CSA was the mean of
the stent CSA in proximal, mid and distal parts of the lesion.
Lumen CSA was calculated at the narrowest part of the lesion.
When the plaque encompassed the catheter, the lumen was
assumed to be the size of the imaging catheter (1.0 mm). The
IH CSA was calculated as stent CSA minus the lumen CSA.
Statistics. Results are presented as mean 6 SD, or n (%).
Comparisons were done with the two-tail Student t test, and
statistical significance was defined at the level p , 0.05. The
data were entered in a FileMaker Pro 2.1 (Claris Corp., Santa
Clara, California) database and transferred to the statistical
program StatView 4.1 (Abacus Concepts, Inc., Berkeley, Cal-
ifornia) for analysis. The composite outcome of death, bypass
surgery or Q-wave infarction within the hospital stay, was used
Abbreviations and Acronyms
CABG 5 coronary artery bypass surgery
CSA 5 cross-sectional area
IH 5 intimal hyperplasia
ISR 5 in-stent restenosis
IVUS 5 intravascular ultrasound
PTCA 5 percutaneous transluminal coronary angioplasty
QCA 5 quantitative coronary analysis
RA 5 rotational atherectomy
TVR 5 target vessel revascularization
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as the short-term end point, and the repeat ISR and TVR as
the long-term end point. The contribution of clinical, angio-
graphic and procedural variable to the TVR was calculated by
univariate analysis and logistic regression analysis in a stepwise
logistic regression model where selection of variables was
achieved in a stepwise fashion. Probability values ,0.05 were
considered significant.
Results
Patient characteristics (Table 1). Significant angina (Ca-
nadian Cardiovascular Society class III to IV) was the present-
ing symptom in 66% of patients and nine patients had non–
Q-wave myocardial infarction (CK-MB .33 normal). Mean
duration from stent implantation to ISR was 154 6 46 days
(range 58 to 501 days). Early ISR, defined as ,90 days of stent
implantation, was present in 18 patients. Two or more conven-
tional risk factors for coronary artery disease (hypertension,
hypercholesterolemia, diabetes mellitus, smoking and family
history) were present in 53% of cases. The Palmaz–Schatz
stent was involved in 90% of cases; seven were coil stents
(Gianturco–Roubin) and three had a tubulocellular design.
Two stents (15 to 20 mm in length) had been used for initial
stent implantation in 42% of cases and three or more in 19%.
Multivessel disease was present in 28%, and nine patients
required additional revascularization for other significant le-
sions. The mean left ventricular ejection fraction (LVEF) was
45% (with EF ,30% in 14 patients). Abciximab (ReoPro) was
used in 32 patients—very liberally in the initial 20 cases, but
later only in cases of long lesion length (.30 mm) or if patient
developed slow flow or chest pain during intervention. The
initial stent was deployed for a restenotic lesion in 22% of
cases.
Angiographic and procedural characteristics (Table 2).
The target lesion and vessel was the left anterior descending
artery in 51%, right coronary artery in 30%, circumflex in 16%
and saphenous vein graft in 3%. The mean lesion length was
17 6 11 mm with 81% being diffuse (.10 mm in length). The
ACC/AHA type C lesion characteristics were present in 53%,
mostly due to .20 mm lesion length. The mean burr-to-artery
ratio was 0.68 6 0.18, with 32 patients having a ratio of ,0.6,
mostly in the beginning (22 out of the first 40). Postdilatation
with a noncompliant balloon at a mean inflation pressure of
4.2 6 2.1 atm was performed in 90 cases. In the remaining 10
cases, adjunctive PTCA was not performed because a satisfac-
tory angiographic lumen post RA had been achieved. Other
procedural characteristics are shown in Table 2.
Acute angiographic results (Table 3). Quantitative coro-
nary analysis (QCA) revealed a stepwise significant increase in
minimum luminal diameter after RA (0.86 6 0.28 to 1.89 6
0.21 mm; acute gain of 1.05 6 0.18 mm) and adjunct PTCA
(2.56 6 0.29 mm; net acute gain of 1.74 6 0.22 mm). After RA
(before adjunct balloon dilatation), despite intracoronary ni-
troglycerin, the reference vessel diameter was slightly less than
the baseline, most likely due to vasospasm caused by the
rotablation. The minimum luminal diameter of 1.89 mm after
RA was smaller than the maximal mean burr size (2.15 mm) in
this series. The exact reason for the disparity was unclear but
Table 1. Baseline Clinical Characteristics (n 5 100)
Age (yrs) 62 6 12
Male gender 72%
CCS class III–IV 66%
Non–Q-wave MI 9%
Time to in-stent restenosis (days) 154 6 46
Early in-stent restenosis (,90 days) 18%
.2 risk factors for CAD 53%
LVEF% mean 45 6 16
LVEF ,30% 14%
Palmaz–Schatz stent 90%
Abciximab use 32%
Multivessel disease 28%
Initial stent in restenotic lesion 22%
CAD 5 coronary artery disease; CCS 5 Canadian cardiovascular society;
LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction.
Table 2. Angiographic and Procedural Characteristics (n 5 100)
Angiographic characteristics
Vessel involved
LAD 51%
RCA 30%
LCX 16%
SVG 3%
Total occlusion 8%
Ostial lesion 11%
ACC/AHA type C lesion 53%
Diffuse in-stent restenosis 81%
Lesion length (mm) 17 6 11
Lesion length
,10 mm 19%
10–20 mm 30%
.20 mm 51%
Procedural data
Burr-to-artery ratio 0.68 6 0.18
Maximum burr size (mm) 2.15 6 0.16
Burr number 2.2 6 0.3
Total ablation time (s) 212 6 110
Balloon size (mm) 3.2 6 1.2
Mean inflation pressure (atm) 4.2 6 2.1
Duration of inflation (s) 120 6 40
ACC/AHA 5 American College of Cardiology/American Heart Association;
LAD 5 left anterior descending; LCX 5 left circumflex; RCA 5 right coronary
artery; SVG 5 saphenous venous graft.
Table 3. Quantitative Coronary Analysis (n 5 100)
Analysis
Pre RA
(n 5 100)
Post RA
(n 5 100)
Post RA1PTCA
(n 5 90)
RVD (mm) 3.16 6 0.31 2.81 6 0.18 3.13 6 0.23
MLD (mm) 0.86 6 0.28 1.89 6 0.21* 2.56 6 0.29*
Diameter stenosis (%) 73 6 8 33 6 10* 18 6 6*
*p , 0.01 compared to pre RA. MLD 5 minimum luminal diameter;
PTCA 5 percutaneous transluminal coronary angioplasty; RA 5 rotational
atherectomy; RVD 5 reference vessel diameter.
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postulated to be some plaque compression in the stented vessel
during ablation immediately followed by reexpansion after the
completion of ablation. In all cases, angiographic contour of
the vessel appeared smooth without any major dissection (Fig.
1, A to C).
Quantitative IVUS analysis (Fig. 2). Three sets of IVUS
images (baseline, post RA and post–adjunct PTCA) in the first
10 and later 27 cases were analyzed to understand the mech-
anism of luminal gain after RA and to evaluate the safety of
RA in this setting. In the 27 later cases, after RA, lumen CSA
increased from 2.4 6 0.5 mm2 to 4.4 6 0.9 mm2 (acute gain of
2.0 mm2 despite a maximal mean burr size of 2.15 mm). After
adjunct PTCA, lumen CSA increased to 5.0 6 1.1 mm2
(additional acute gain of 0.6 mm2) due to additional reduction
of restenotic tissue. The stent CSA remained unchanged in our
series, perhaps due to the use of low-pressure balloon infla-
tions. Therefore, 77% of the luminal gain was attributable to
rotational ablation of restenotic plaque and 23% to adjunct
PTCA causing compression and/or extrusion of the neointimal
tissue (Fig. 3A to C). Stent reexpansion did not contribute to
the luminal enlargement. In 22% of the cases, IVUS revealed
that stents were not fully deployed (defined as minimal stent
area ,80% of the distal reference vessel area), but high-
pressure balloon dilatation to further expand the stent struts
after RA was not performed to remain consistent with the trial
design of low-pressure balloon dilatation after RA. There were
no cases of stent distortion, breakage, wire protrusion, perfo-
ration or intimal dissection.
In-hospital course. All procedures (100%) were successful
angiographically with ,30% diameter stenosis without the use
of additional stents. There were no major angiographic dissec-
tions or cases of burr entrapment. Minor angiographic dissec-
tions were noted in 7%. Slow flow occurred in three patients.
The short-term composite end point of death, bypass surgery
or Q-wave infarction during the hospital stay, did not occur in
any patient. One patient developed a femoral artery pseudo-
aneurysm requiring duplex ultrasound-guided compression
and one required blood transfusion for a moderate-sized groin
hematoma. Creatine kinase-MB enzyme elevation above base-
line occurred in 11 patients, with .33 normal in 2 patients.
Late clinical results. All patients have completed at least 9
months of follow-up, with a mean of 13 6 5 months. Five
Figure 1. Cineangiograms of diffuse ISR treated with RA and adjunc-
tive PTCA. (A) Diffuse ISR (arrow) of the right coronary artery 94
days after three 3.5 mm Palmaz–Schatz stents implantation. (B) Thirty
percent residual stenosis (arrow) post RA using 1.5, 2.0 and 2.25 mm
rota burrs. (C) Less than 10% residual stenosis (arrow) post
RA1PTCA using a 3.5/30 mm compliant balloon at 6 atm.
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patients presented with uncomplicated non–Q-wave myocar-
dial infarction due to repeat in-stent occlusion. There were no
Q-wave myocardial infarctions. Recurrent ISR occurred in
28% (28 of 100) at a mean duration of 102 6 52 days. Of these
28 patients, 2 were treated medically (due to total occlusions)
and 6 were referred for coronary artery bypass graft (CABG)
surgery. The other 20 patients underwent repeat percutaneous
interventions: 8 underwent PTCA alone, 7 underwent repeat
RA plus adjunct PTCA and 5 underwent repeat stent implan-
tation. Therefore, TVR occurred in 26% of cases. During the
follow-up period, 4 additional patients required percutaneous
intervention of a nontarget vessel. At the completion of
follow-up, 98 patients were alive (1 patient died post CABG
and the other died suddenly 2 months after repeat stent
implantation).
Predictors of repeat ISR (Table 4). To evaluate the pre-
dictors of repeat ISR after RA, various clinical, angiographic
and procedural factors were analyzed by univariate and step-
wise regression analysis. A burr-to-artery ratio of ,0.6 was the
strongest predictor of repeat ISR (64% vs. 19%, p , 0.0001;
odds ratio [OR] 7.46). Early ISR in ,90 days of stent
implantation was significantly associated with recurrence com-
pared to ISR occurring after 90 days of stent implantation
(39% vs. 10%, p , 0.001; OR 6.0). Other predictors of repeat
ISR were: ostial lesion, ACC/AHA type C lesion, initial stent
implantation for a restenotic lesion and diffuse type ISR.
Various other factors such as diabetes mellitus, unstable
angina, LVEF ,30%, use of abciximab, vessel disease, total
ablation time and final minimum luminal diameter were not
associated with recurrence.
Discussion
Rational of RA for ISR. Treatment of ISR has become an
increasingly common challenge due to the continued growth of
coronary stenting in a wide variety of coronary lesions. The
vessel wall pathology in ISR consists of a nonrecoiled metallic
stent (16) that provides a round scaffolding within which
neointimal tissue proliferates and narrows the lumen (4,5).
Angiographically, most ISR is of the diffuse type (40% to 78%)
characterized by neointimal hyperplasia and a poor response
to high-pressure balloon redilatation causing tissue compres-
sion and extrusion and plaque reexpansion (8–10). The diffuse,
circumferential distribution of IH in (in-stent) restenotic le-
sions may favor rotational ablation by preventing direct contact
between the rotablator burr and the stent struts. Furthermore,
ablation rather than tissue compression and extrusion alone
may offer an improvement in the treatment of ISR. Given the
poorly characterized interaction between the rotablator and
the metallic stent surface, interventional cardiologists have
been skeptical regarding the use of RA for ISR (11,12).
However, on theoretical grounds it is difficult to argue that
stainless steel microparticles present a greater risk to the
microcirculation than do microparticles derived from calcified,
fibrotic, atherosclerotic plaque. In fact, it has been our expe-
rience that ISR patients tolerate aggressive RA more easily
than patients with de novo calcified lesions.
Comparison with other studies. This study demonstrated
the safety and efficacy of RA for the treatment of ISR. Our
results showed an 100% safety rate, even with a burr-to-artery
ratio of 0.7 in later cases (compared to a smaller burr-to-artery
ratio of 0.55 in the first 20 cases). Rather, RA in ISR cases was
very well tolerated with a very low incidence of slow flow (3%)
despite a high prevalence of long lesions (51% being .20 mm).
Also, with the present recommended technique of step burr
approach, there were no unusual complications of burr entrap-
ment, perforation and obvious stent distortion/damage on
angiography or IVUS. Despite the initial experience in this
field, there were no major ischemic procedure-related compli-
cations. Abciximab was used in 32% of our cases largely in the
beginning, not knowing how RA would be tolerated in this
setting. Later in the series it became evident that RA for ISR
Figure 2. Quantitative IVUS analysis of
the mechanism of lumen enlargement
after RA and adjunct PTCA.
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is well tolerated and abciximab use was limited to very long
lesions, cases of slow flow and significant chest pain or
electrocardiographic changes during the intervention. None-
theless in our series, abciximab use was not associated with
lower TVR. Our long-term results showed a lower clinical
restenosis rate (28%) and lower TVR (26%) compared with
historic controls of PTCA in the treatment of ISR (6–
10,17,18). Although in the present study there was no control
group for direct comparison of ISR treatment by various
techniques, our single center results have revealed TVR of
62% after PTCA and 40% after restent implantation for
diffuse ISR treatment (10). With respect to diffuse ISR, our
group had a TVR of 32% compared to 85% reported by Yokoi
et al. (8). A recent report by Reimers et al. (19) revealed a low
clinical restenosis (20%) and a low TVR rate of 11% after
percutaneous intervention of ISR at a mean follow-up of 27.4
months. A relatively better outcome in this series of predom-
inately PTCA-treated ISR was most likely attributed to a high
number of patients with focal ISR (62% compared to 19% in
our series). A multicenter BARASTER registry evaluated the
early and long-term results of RA for ISR and revealed a high
clinical success rate of 97.4% and 2.2% major complications
(20). In this cumulative series of 153 lesions from 10 centers,
recurrent restenosis occurred in 48% (57% with RA alone vs.
35% after RA 1 adjunct PTCA; p , 0.01). The relatively high
recurrence rate in the BARASTER registry compared with
28% in our series may be due to the heterogeneous patient
population, a small reference vessel size (2.75 6 0.41 mm vs.
3.16 6 0.31 mm in our series) and a lower final minimum
luminal diameter (2.11 6 0.41 mm vs. 2.56 6 0.29 mm in our
series). Moreover, the BARASTER registry demonstrated the
importance of adjunct PTCA even after optimal RA (high
burr-to-artery ratio of 0.76) in further reducing the recurrent
restenosis. There is little difference in the TVR of 26% after
RA in our series and the TVR of 21% after excimer laser
angioplasty previously reported by Mehran et al. (10). The
laser study included patients with several differences compared
Figure 3. Intravascular ultrasound images of diffuse ISR treated with
RA and adjunctive PTCA. (A) Diffuse restenotic plaque (IH) area
(single arrow) in a well-deployed 3.75 mm Palmaz–Schatz stent
(double arrows). (B) Significant decrease in plaque thickness (single
arrow) after 2.25 mm rota burr and improvement in lumen area
(double arrows). (C) Additional luminal enlargement (single arrow)
after dilatation with a 4.0 mm compliant balloon at 4 atm. There was
no change in the stent CSA (double arrows).
Table 4. Univariate Predictors of Recurrent In-stent Restenosis
after Rotational Atherectomy
Variables
Restenosis
(n 5 28)
(%)
No
restenosis
(n 5 72)
(%) p Value OR
Burr-to-artery ratio
# 0.6
18 (64) 14 (19) , 0.001 7.46
Early ISR (, 90 days) 11 (39) 7 (10) , 0.001 6.00
Ostial lesion 7 (25) 4 (6) 0.01 5.66
AHA/ACC type C
lesion
20 (71) 33 (46) 0.02 2.95
Initial stent in restenotic
lesion
10 (36) 12 (17) 0.04 2.78
Diffuse ISR 26 (93) 55 (76) 0.05 2.56
LVEF , 30% 6 (21) 8 (11) 0.18
LAD location 17 (61) 34 (47) 0.22
Unstable angina 19 (68) 47 (65) NS
Diabetes mellitus 8 (29) 16 (22) NS
Abciximab use 7 (25) 25 (35) NS
Total ablation time (s) 228 6 101 201 6 109 NS
Final MLD (mm) 2.54 6 0.21 2.59 6 0.26 NS
ISR 5 in-stent restenosis; LAD 5 left anterior descending artery; LVEF 5
left ventricular ejection fraction; MLD 5 minimum luminal diameter; OR 5
odds ratio.
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with our study population, including a relatively shorter
follow-up period (5.4 vs. 13 months), more patients with short
lesions ,10 mm (53% vs. 19%), smaller vessel size (reference
vessel diameter 2.64 6 0.5 vs. 3.16 6 0.31 mm), more saphe-
nous vein graft interventions (36% vs. 3%) and more aorto-
ostial lesions (26% vs. 11%). At present there is no direct
comparative analysis of RA versus laser for treatment of ISR.
In a small series, directional coronary atherectomy has been
shown to be safe and effective for the treatment of ISR
involving large stents (.3.5 mm), but long-term data are
lacking and stent fragments have been retrieved in some cases
(21).
Mechanism of luminal enlargement. The QCA and IVUS
analyses indicated that the major part of the luminal gain was
attained after RA (77%), with a small contribution by the
adjunct low-pressure balloon dilatation. Mehran et al. (10)
reported on the mechanism of luminal enlargement after
excimer laser and adjunct high-pressure PTCA, showing a 40%
contribution from additional stent expansion and a relatively
equal contribution from laser ablation (29%) and adjunct
PTCA (31%). The absence of stent expansion and the limited
contribution of plaque compression and extrusion to the
reduction of the percent area stenosis in our study is likely due
to aggressive rotablation (mean maximum burr size of
2.15 mm) and the use of low- rather than high-pressure balloon
dilatation (4.2 6 2.1 vs. 16.5 6 3.1 atm after laser) without
oversized balloons (balloon-to-artery ratio 1:1 vs. 1.4:1 after
laser).
Predictors of repeat TVR. Our analysis of predictors of
recurrent ISR and TVR revealed that recurrent ISR after RA
correlated with several characteristics that have also been
associated with recurrent restenosis after balloon angioplasty
such as ostial lesion, stent implantation for a restenotic lesion,
ACC/AHA type C lesion and diffuse ISR lesions (17). Subop-
timal debulking with small rota burrs (burr-to-artery ratio
,0.6) correlated with a very high recurrence. This probably
represents more PTCA effect rather than ablation in these
cases. Of interest, similar to reports by Reimers et al. (19),
early ISR within 90 days of stent implantation was found to be
a strong correlate of recurrence after RA. Early ISR is
probably a marker of very aggressive vascular response to
injury caused by initial stent implantation, and even successful
rotational ablation may not alter this aggressive intimal hyper-
plastic response.
Study limitations. The present study has several important
limitations which should be considered before interpreting the
final results. This study evaluated mainly ISR of Palmaz–
Schatz stents (90%) and had no direct control group undergo-
ing PTCA. Patient selection may therefore present a bias in the
comparison of our results with historic controls of PTCA. We
demonstrated a TVR of 26% in after RA for treatment of
predominantly diffuse ISR lesions (81%), which is lower than
the average TVR of 45% reported in the literature in this
setting after PTCA. In addition, there was no routine angio-
graphic follow-up (follow-up angiograms .3 months after RA
are available in 44%). This may underestimate the incidence of
recurrent angiographic ISR that may be clinically silent. Be-
cause the main aim of the present study was to reduce clinical
restenosis, all patients were closely followed for clinical events
and recurrence, as well as noninvasive testing. Finally, system-
atic IVUS analysis was performed in only 45 cases, with
interpretable data in 37 patients, and the exact contribution of
tissue compression versus tissue extrusion could not be deter-
mined. Also, if preprocedure IVUS revealed an underde-
ployed stent, a high-pressure balloon dilatation after RA was
not used, to remain consistent with the trial design. Nonethe-
less, there were no major procedural complications, stent
damage or burr entrapment in these patients, perhaps due to
the presence of restenotic tissue covering the stent struts,
thereby preventing burr-to-stent contact.
Conclusions and clinical implications. To our knowledge
the present study reports the largest cohort of patients with ISR
treated using RA. We have found that RA is safe and very well
tolerated in the setting of ISR, particularly in comparison to RA
of long, calcified lesions. These preliminary findings support the
use of RA as a routine procedure for the treatment of diffuse ISR
where PTCA appears to yield suboptimal acute angiographic
results and a high restenosis rate. Based on these encouraging
results, an IVUS-guided randomized trial comparing RA (burr-
to-artery ratio 0.7) followed by low-pressure (3–6 atm) balloon
dilatation to high-pressure (12–16 atm) PTCA for treatment of
ISR (ROSTER trial) has been started (22).
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